Several TAM pharmacogenetic studies have been published in breast cancer patient cohorts [37] but to our knowledge, this is the first pharmacogenetic study evaluating the effect of CYP2D6*17 on the pharmacokinetics and metabolism of TAM and its metabolites in a controlled black healthy subjects’ population. The gene discussed is CYP2D6; the disease is breast cancer.